gone colorectal surgery for resection of cancer and benign lesions are at risk for recurrent, residual, or metachronous lesions at the anastomosis site. Surgical resection of such lesions is difficult because of adhesions, and a stoma may be required as there are risks for leakage after resection. The feasibility and safety of endoscopic submucosal dissection (ESD) for these lesions remain unknown. Therefore, this case series aimed to examine the feasibility and safety of ESD by evaluating the clinical outcomes.
Patients and methods We retrospectively investigated
five patients who underwent ESD by a single expert for superficial neoplastic lesions at the anastomosis site after previous colorectal surgery.
Results R0 resections were achieved for all lesions. Mean procedure time was 160.6 minutes. Mean dimensions of the resected specimen and tumor were 52.4 mm and 31.8 mm, respectively. None of the patients had complications or recurrence after surveillance colonoscopy 1-year post-resection.
Conclusions
In an expert's hands, ESD at the anastomosis site might be feasible minimally invasive treatment for superficial neoplastic lesions.
of staples from the previous surgery. Surgical resection can be also difficult based in the case of adhesions, and a stoma may be required [7] . ESD for lesions at the AS may have advantages for minimally invasive treatment, therefore, we report on our technical tips and outcome of ESD.
Patients and methods

Patients
We conducted a retrospective review of five patients with superficial neoplastic lesions on the AS after colorectal resection, who underwent ESD at our hospital and affiliated hospitals between July 2007 and March 2017. The ESDs were performed by a single highly experienced endoscopist. A tumor developing on the AS or a lesion spanning into the AS is defined as "a tumor at the AS." Indications for ESD based on the colorectal ESD/ Endoscopic mucosal resection guidelines were issued by the Japan Gastroenterological Endoscopy Society [2] . Informed consent was obtained from all patients before the procedure, after explained patients for the procedure, results, and possible complications such as perforations.
ESD equipment and procedure
The procedures were performed using a single-channel endoscope (PCF-Q260, GIF-Q240, or GIF-H260; Olympus Corporation, Tokyo, Japan) with FlushKnife BT 1.5 mm (DK2620J-B15S; FTS, Tokyo, Japan) and FlushKnife N 1 mm (DK2620J-N10S; Fujifilm Medical Co., Ltd., Tokyo, Japan). A small-caliber-tip transparent hood (ST Hood) (DH-28GR; Fujifilm Medical Co., Ltd., Tokyo, Japan) or a transparent hood with slit and hole (F-25 or F-40; Top Co., Ltd. Tokyo, Japan) was used to maintain good visibility in the operative field. In all cases, 0.4 % sodium hyaluronate (MucoUp, Boston Scientific Co., Tokyo, Japan) was used for submucosal lifting. Procedure time was defined as the time between mucosal injection and complete resection. Four patients underwent ESD under conscious sedation and one patient under general anesthesia.
Mucosal incision started from the anal to oral site of the nonfibrotic area, and the submucosal layer was opened. A mucosal flap of the normal mucosa, which was further from the tumor margin (approximately 5 -10 mm) in contrast to that in conventional ESD, was created. Finally, the severely fibrosed part was dissected to connect both ends of the non-fibrotic areas (▶ Fig. 1 ). Swift Coag Effect 2, 50 -100 W or Drycut mode Effect 3, 100 W of VIO 300 D (ERBE Elektromedizin, Tubingen, Germany) was used to dissect the severely fibrotic parts. After exposing, the staples were removed using biopsy forceps to the greatest extent possible, because of a probability of high-frequency current being conducted from the target lesion to the staples, which have a low electrical resistance. In cases where staple removal was difficult, the excision line was made below the staples within the thickened muscularis propria due to anastomosis [8] . This was carefully performed with a FlushKnife N 1.0-mm device, which has the shortest electrode knife, to avoid the damage to the deep muscle layer (▶ Fig. 2 ).
Results ESD was performed in five patients (▶ Table 1 ) with lesions at the AS. Two patients had residue from surgical resection performed for removal of a superficial rectal neoplasm. The remaining three patients had metachronous lesions that had developed from FAP and UC. R0 en bloc resection was achieved in all cases. No patient had bleeding with need for endoscopic he- Beige, tumor; dark beige, severely fibrosed area; light blue, background normal mucosa. a Tumor spread to both the oral and anal sides of the anastomosis line. b Mucosal incision is initiated from the non-fibrotic mucosa (white line), and submucosal dissection proceeds along the tumor. A complete mucosal flap is created by dissecting the submucosal layer in the mildly fibrosed or non-fibrosed area (gray-shaded area). c Finally, the severely fibrosed area (dark beige) is dissected in the direction of the white dotted line to complete tumor removal. mostasis or perforations with free intraperitoneal gas that could be detected on a plain radiograph. Mean procedure time was 160.6 minutes. Mean dimensions of the resected specimen and tumor were 52.4 × 32.8 mm and 31.8 × 18.8 mm, respectively. All patients were discharged to their homes within 1 week after ESD. No recurrence was found during the 1-year surveillance colonoscopy. There was no stenosis after ESD except Case #5 in which the patient had a circumferential lesion. However, the stenosis was improved by weekly balloon dilatation and daily digital self-dilatation after 3 months.
In Case #1, the patient previously underwent laparoscopic right hemicolectomy with low anterior resection for large mucosal neoplasms in the hepatic flexure and rectum. One year later, residual rectal lesions at the AS were detected and removed by two transanal resections. However, two skipped recurrent lesions appeared at the AS. The patient underwent ESD procedure for these lesions. ▶ Fig. 3 shows representative endoscopic images from Case #1. ▶ Video 1 shows the ESD procedure for Case #1.
Discussion
After oncologic resection, patients with colorectal cancer still have a high risk of developing recurrent, residual, or metachronous lesions. FAP and UC are notorious for increasing risk of developing colorectal cancer [1, 9] . In these cases, we reviewed five patients who underwent ESD for superficial neoplastic lesions at the AS. ESD may be a good treatment option, as it is minimally invasive and can prevent complications from surgery. Re-operation in these patients is technically difficult because of multiple adhesions. Furthermore, four patients had lesions in the narrow pelvic cavity that are difficult to operate on. Ileoanal anastomosis surgery after subtotal colectomy is a common procedure for treatment of UC to prevent cancer recurrence. However, it can affect defecation function and cause significant deterioration in quality of life [10] . Therefore, ESD may be a better procedure for preserving defecation function compared to reoperation, such as in Case #3.
Two patients underwent subtotal colectomy with ileorectal J-pouch anastomosis, one patient underwent total proctocolectomy, and one patient underwent right hemicolectomy. ESD on the ileal side was difficult because the ileum wall is thinner than the colorectal wall. Particularly, the lesion in Case #2 required careful handling, because it was located at the anastomosis of the transverse colon and the ileum which, if perforated, can lead to leakage into the intraperitoneal cavity [11] . For this case, due to the tumor location, surgery is assumed to be relatively easier and safer compared with cases requiring low rectal anastomosis. Therefore, if it is judged that ESD is technically difficult with some conditions of adhesions and unstable endoscopic maneuverability, surgery should be considered.
Another treatment options for these cases is transanal endoscopic microsurgery (TEM), which can achieve full-thickness resection. Kawaguti et al. compared ESD and TEM in a single-center study in which local recurrence rates were 9.1 % and 18.1 % in the ESD and TEM groups. Although no significant differences were found between the two groups, there was a tendency for a higher risk of local recurrence in the TEM group, especially in the case of large lesions [12] . TEM has been speculated to be unsuitable for circumferential lesions [13] . A full-thickness resection using an over the-scope device may be considered as another treatment option, however, R0 resection rate is as low as 58.1 % for > 2 cm lesions in this study [14] . For lesions > 2 cm in our cases, the en bloc resection rate of ESD was 100 %, no recurrences were observed after 1-year follow-up, including in cases of recurrent lesions after a TEM procedure (Case #1) and circumferential lesion (Case #5). Therefore, ESD could have more advantages as seen in our cases.
However, our cases have some important limitations. A small number of cases were analyzed, and all procedures were performed by a single experienced endoscopist. The lesions included in our cases were already difficult cases, and the results may not be applicable if the technique is carried out by less ex- The excision line ▶ Fig. 2 The appropriate excision line for the anastomotic site. The excision line (yellow dash line) at the anastomotic site was made below the staples within the thickened muscle layer.
▶ Table 1 Clinical characteristics of five patients with a lesion at the anastomotic site. 
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perienced endoscopists. Therefore, ESD in such cases should only be performed by well-experienced doctors. It should be kept in mind that it could expose patients to risk of adverse events, such as perforation, if it is done by less experienced endoscopists. In those hospitals without ESD experts, surgery should always be considered as the treatment option.
Conclusion
In an expert's hands, ESD is a feasible treatment strategy for superficial neoplastic lesions at the AS. En bloc resection can be achieved with this minimally invasive method and decrease risk of anastomosis leakage and possible stoma creation by surgery.
Competing interests
Takashi Toyonaga invented the FlushKnife and FlushKnife-BT in conjunction with Fujifilm Inc., Tokyo, Japan and receives royalties from its sale.
